Childhood acute myeloid leukaemia

Rubnitz, JE; Inaba, H

HERO ID

2810886

Reference Type

Journal Article

Subtype

Review

Year

2012

Language

English

PMID

22966788

HERO ID 2810886
Material Type Review
In Press No
Year 2012
Title Childhood acute myeloid leukaemia
Authors Rubnitz, JE; Inaba, H
Journal British Journal of Haematology
Volume 159
Issue 3
Page Numbers 259-276
Abstract Although acute myeloid leukaemia (AML) has long been recognized for its morphological and cytogenetic heterogeneity, recent high-resolution genomic profiling has demonstrated a complexity even greater than previously imagined. This complexity can be seen in the number and diversity of genetic alterations, epigenetic modifications, and characteristics of the leukaemic stem cells. The broad range of abnormalities across different AML subtypes suggests that improvements in clinical outcome will require the development of targeted therapies for each subtype of disease and the design of novel clinical trials to test these strategies. It is highly unlikely that further gains in long-term survival rates will be possible by mere intensification of conventional chemotherapy. In this review, we summarize recent studies that provide new insight into the genetics and biology of AML, discuss risk stratification and therapy for this disease, and profile some of the therapeutic agents currently under investigation.
Doi 10.1111/bjh.12040
Pmid 22966788
Wosid WOS:000309717500003
Is Certified Translation No
Dupe Override No
Is Public Yes
Language Text English
Keyword acute myeloid leukaemia; AML; childhood leukaemia